Literature DB >> 18980088

Prevalent platelet dysfunction in patients with aortic valve disease.

Wolfgang Prohaska1, Armin Zittermann, Jan U Lüth, Kazuo Inoue, Wilhelm Köster-Eiserfunke, Detlev Baller, Reiner Körfer, Knut Kleesiek.   

Abstract

BACKGROUND AND AIM OF THE STUDY: In patients with heart valve disease, the valve leaflets display a gapped, rough endothelial lining often covered with calcified areas. As a consequence, blood flow is disturbed and a stimulation of components of the hemostasis system is assumed. The possible mechanisms of this process are, however, unclear at present.
METHODS: Platelet function was studied in 660 patients considered for isolated coronary artery bypass graft (CABG) surgery, and in 421 patients considered for single aortic valve replacement (AVR). Platelet function was monitored preoperatively using the platelet function analyzer device (PFA-100). The test results were reported as closure time of the membrane hole at the end of a capillary tube. The von Willebrand factor antigen, and its collagen-binding activity, were also determined among subgroups of 40 AVR and 50 CABG candidates.
RESULTS: Platelet dysfunction was displayed by only 22% of CAD patients, but by 83% of AVR candidates. The mean PFA closure time in AVR patients was considerably higher than in CAD patients (231 +/- 59 s versus 153 +/- 60 s, respectively; p < 0.01). The mean platelet volume, platelet distribution width and von Willebrand factor collagen binding and antigen levels did not differ between the patient groups.
CONCLUSION: It is assumed that, due to disturbed flow and shear exposition, following an initial activation, the platelets are partially degranulated, shed microparticles, and might become involved in the pathogenesis of microvascular dysfunction and thrombotic events in patients with aortic valve disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980088

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  7 in total

1.  Thrombogenic potential of transcatheter aortic valve implantation with trivial paravalvular leakage.

Authors:  Lawrence N Scotten; Rolland Siegel
Journal:  Ann Transl Med       Date:  2014-05

Review 2.  Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR).

Authors:  Abhishek Sharma; Sunny Goel; Carl J Lavie; Armin Arbab-Zadeh; Debabrata Mukherjee; Jason Lazar
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

Review 3.  Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation.

Authors:  Donald R Lynch; David Dantzler; Mark Robbins; David Zhao
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

4.  Serotonin receptor type 2B activation augments TNF-α-induced matrix mineralization in murine valvular interstitial cells.

Authors:  Felicia Fong; Joshua Xian; Linda L Demer; Yin Tintut
Journal:  J Cell Biochem       Date:  2020-09-09       Impact factor: 4.429

Review 5.  Serotonin-A Driver of Progressive Heart Valve Disease.

Authors:  Helge Waldum; Alexander Wahba
Journal:  Front Cardiovasc Med       Date:  2022-01-28

6.  Platelet-to-Lymphocyte Ratio May Predict the Severity of Calcific Aortic Stenosis.

Authors:  Serkan Akdag; Aytac Akyol; Muntecep Asker; Ramazan Duz; Hasan Ali Gumrukcuoglu
Journal:  Med Sci Monit       Date:  2015-11-06

7.  Higher Preoperative Plasma Thrombin Potential in Patients Undergoing Surgery for Aortic Stenosis Compared to Surgery for Stable Coronary Artery Disease.

Authors:  Axel Dimberg; Ulrica Alström; Elisabeth Ståhle; Christina Christersson
Journal:  Clin Appl Thromb Hemost       Date:  2018-05-16       Impact factor: 2.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.